MarketBeatMAY 83 min read$TCMD

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of "Moderate Buy" from Analysts

Tactile Systems Technology, Inc. (NASDAQ:TCMD) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $38.60. Despite missing EPS estimates, the company exceeded revenue expectations in its latest quarter. Insider selling was observed, but institutional ownership remains high, with several major funds increasing or establishing positions.

Original reporting

MarketBeat · MarketBeat

Published May 8, 2026, 6:56 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI May 8, 2026, 7:30 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · MarketBeat

Decision brief

The 30-second read

$TCMDBullishMed

Why it matters

The analyst consensus and institutional interest indicate positive sentiment, but earnings miss and insider selling introduce some uncertainty.

Market read

The news is highly relevant for investors in the healthcare device sector and those holding or considering TCMD shares.

What to watch

Potential upcoming regulatory changes or sector-wide shifts that could impact performance are not discussed.

Relevance 6/10Timing: Short to medium term (1-3 months)

Background

Tactile Systems Technology, Inc. specializes in medical devices for vascular and lymphedema conditions. Recent earnings reports show mixed results, with revenue exceeding expectations but EPS missing estimates.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TCMDBullishMedium confidence

Context

High relevance due to analyst ratings and institutional activity.

Expected impact

Moderate upward movement within the next 1-3 months, approximately 10-15% increase.

Evidence & confidence

Analyst consensus and institutional buying support positive outlook, but earnings miss and insider selling introduce some risk.

Market effects

Sector

Potential positive influence on the medical device and life sciences sectors due to company-specific developments.

Regional

Limited regional impact; primarily affects investors focused on US markets.

Global

Minimal global market impact given company size and sector.

Counterpoint

What could challenge this read

The earnings miss and insider selling could signal underlying issues, suggesting caution against aggressive buying.

Key entities

Company
Tactile Systems Technology, Inc.
A medical device company focusing on vascular and lymphedema treatment devices.

Read at source ← All news

AUG 18

$TCMDMedAI 8/10

Tactile Systems Technology (TCMD) Q2 2026 Earnings Call Transcript

Tactile Systems Technology (TCMD) reported Q2 2026 revenue of $85.7M, up 9% Y/Y, driven by lymphedema revenue of $73.6M (+12%). Airway clearance revenue fell 7% to $12.1M due to distributor inventory dynamics. Gross margin was 76.3%. Adjusted EBITDA rose to $11.4M (+49%). FY2026 revenue guidance was set at $360M-$366M and EBITDA at $49M-$51M.

fool.com7 min

AUG 12

$TCMDMed

Tactile Systems Technology, Inc. Q2 2026 Earnings Call Summary

Tactile Systems Technology reported Q2 2026 results: lymphedema revenue rose 12% YoY on Flexitouch adoption, while airway clearance revenue fell 7% as large DME partners paused orders amid elevated inventory. Gross margin increased 180 bps to 76.3%. Full-year 2026 revenue guidance was raised to $360m-$366m; MyoSleeve launch and LymphaTech FDA submission are ongoing.

yahoo.com7 min

AUG 10

$TCMDHigh

Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results

TACTILE SYSTEMS TECHNOLOGY INC (TCMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results MINNEAPOLIS, MN, August 10th, 2026 – Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with ch

SEC EDGAR 8-K6 min

JUN 2

$TCMDMedAI 8/10

Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy

Tactile Medical (Nasdaq: TCMD) announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation system. The company says it keeps the same use for chronic neuromuscular and respiratory conditions such as cystic fibrosis and bronchiectasis across ages, while adding a lighter, more adjustable vest and a redesigned controller. It also includes built-in Wi‑Fi/Bluetooth for connected care and clinician/payer data.

manilatimes.net4 min

OCT 19

$JPMLow

JPMorgan Chase is Delving Further Into National Security With $5 Billion Push

JPMorgan Chase has invested over $5 billion in U.S. national security and industrial capacity, exceeding initial plans. The bank may expand its $10 billion commitment, with investments in defense, manufacturing, and frontier technologies. Recipients include Hadrian and Castelion, focusing on automated factories and hypersonic missiles. The initiative aims to reduce foreign dependence and support long-term growth.

finance.yahoo.com2 min